Process and Product Development Subcommittee

Charter

The Process and Product Development Subcommittee strives to:

  • Establish and communicate best practices in Process and Product Development (PPD) as it relates to therapeutic cell based products.
  • Assess emerging cell processing technologies and forecast their impact on the commercialization process.

Click here to view the full charter.

Projects and Objectives

  • Educational Webinars: Process Development is a discipline learned on the job and there are few texts that cover many of the best practices used in the field—and fewer available that discuss Cell Therapy-specific requirements. The Process and Product Development Subcommittee develops educational webinars to cover best practices in Cell Therapy Process Development. Click here to view upcoming webinars.
  • White papers: White papers are an important vehicle for the PPD to educate and influence the field. White papers will be published in peer-reviewed journals to increase credibility and visibility of the PPD and ISCT. Click here to view the published PPD white papers.
  • ISCT Annual Meeting: The PPD will be actively involved in the organization of the ISCT Annual Meeting. At least one session in the Strategies for Commercialization Track will be organized by this committee.

 

 


 

Committee Chair

 


 

Ohad Karnieli, PhD, MBA
Chair
Karnieli Inc.
Haifa, Israel

 

Committee Members

 

Eytan Abraham, PhD
Lonza
Walkersville, MA, United States

Julie Allickson, PhD, MSc, MT(ASCP)
Wake Forest Institute for Regenerative Medicine
Winston-Salem, NC, United States

Myriam Armant, PhD
Harvard Stem Cell Institute
Boston, MA, United States

Thierry Bovy
Pall Life Sciences
Dreieich, Germany

Harvey Brandwein, PhD
Cook Regentec
Port Washington, NY, United States

Christopher Bravery, PhD
Advanced Biologicals Ltd.
London, United Kingdom

Thomas Brieva, PhD
Celgene Cellular Therapeutics
Warren, MI, United States

Scott Burger, MD
Advanced Cell & Gene Therapy
Chapel Hill, NC, United States

Sarah Callens
Cell and Gene Therapy Catapult
London, UK

Frank Fischer
Cook Regentec
Bloomington, IN, United States

Dominic Clarke, PhD
Charter Medical
Winston-Salem, NC, United States

Shannon Eaker, PhD
GE Healthcare 
Knoxville, TN, United States

John Fink, MSc
Brooks Life Science Systems
Chelmsford, MA, United States

David Fiorentini, MSc
Biological Industries
Kibbutz Beit-Haemek, Israel
Mark Leonard
Pfizer
Andover, MA, United States
Michael Mendicino, PhD
Hybrid Concepts International, LLC
Grand Island, NY, United States
Kim Nguyen
Terumo BCT
Lakewood, CO, United States

Steve Oh, PhD
ASTAR
Singapore

Jean-Sébastien Parisse
Asceptic Technologies
Isnes, Belgium

Alaina Schlinker, PhD
Fresenius Kabi
Lake Zurich, IL, United States

Brad Shirley, MSc
Cook Regentec
Indianapolis, IN, United States

Ravenska Wagey, PhD
STEMCELL Technologies
Vancouver, BC, Canada

Amy Wehn, PhD
HTG Molecular Diagnostics
Raleigh-Durham, NC, United States

Maya Fuerstenau-Sharp, MS, PhD
Sartorius Stedim Biotech
Kassel Area, Germany
Charles Golightly, MS, PhD
Pall Corporation
New York City, NY, United States

Erik Woods, PhD
Ossium Health Inc.
Indianapolis, IN, United States

Andrew Campbell, PhD
Thermo Fisher Scientific
Buffalo/ Niagara, NY, United States

Knut Niss, PhD
MustangBio
Boston, MA, United States

 

 


Jean-Sébastien Parisse
Asceptic Technologies
Isnes, Belgium

© 2017 International Society for Cellular Therapy. All rights reserved.
ISCT, International Society for Cellular Therapy, and the ISCT logo are registered service marks of The International Society for Cellular Therapy.
The BEACON and lighthouse logo is a service mark of The International Society for Cellular Therapy.